A major international trial has found that daily fish oil supplements significantly reduced life-threatening cardiovascular events in dialysis patients. People who took four grams per day had a 43% ...

The obesity drug semaglutide (Wegovy) conferred a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including semaglutide for diabetes (Ozempic), an analysis ...

Myocardial ischemia, the primary driver of heart attacks, remains the leading cause of death and disability worldwide. Delays in diagnosis directly correlate with increased myocardial necrosis, higher ...

GlobalData analyst Dr Andrew S Thompson’s states Medtronic could significantly grow Scientia’s micro guidewire franchise if they can replicate its US success on the international stage.

Medtronic today announced its entry into a definitive agreement to acquire Scientia Vascular, a company with critical, innovative technology across the neurovascular portfolio. The acquisition is ...

Medtronic (NYSE: MDT) announced today that it entered into a definitive agreement to acquire Scientia Vascular in a $550 million deal.

The arterial vasculature is the second most frequently calcified structure in the human body after the skeleton. Calcification of the aorta and aortic valves occurs in most individuals in westernized ...

A 65-year-old white woman presented with 9 months of intermittent “kaleidoscopic” visual disturbances and blurred vision upon awakening.Her medical history was significant for hypertension, ...

Cardiovascular disease remains the leading cause of mortality worldwide, necessitating deeper insights into its molecular underpinnings beyond genetic predisposition. Epigenetic modifications, ...

A new study published by the American Heart Association indicates a disheartening finding: the prevalence of cardiovascular ...

Anthony Palumbo and Charles Goulding analyze Boston Scientific’s US$14.5 billion acquisition of Penumbra, showing how additive manufacturing can accelerate thrombectomy and neurovascular innovation ...

Initiation of hormone therapy (HT) after age 65 years is tied to significantly increased risks for cancer and vascular events.